http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
황성규(Seong Gyu Hwang) 대한소화기학회 2001 대한소화기학회지 Vol.37 No.5
Our understanding and treatment of acute hepatic failure have been limited by the lack of satisfactory animal models. The requirements for a satisfactory animal models are reversibility, reproducibility, death from liver failure, the presence of a therapeutic widow, a large animal model, and minimal hazard to personnel. Different models may be required to evaluate the various types of liver failure observed in man. The animal models are established through the methods such as surgical anhepatic and devascularization procedures, as well as hepatotoxins such as galactosamine, CC14 and acetaminophen, thioacetamide. Surgical models have the best reproducibility among animal models, but show potential disadvantages such as inability to recreate the inflammatory milieu that exists in acute hepatic failure and reliance on surgical expertise. The models using hepatotoxins are free of such constraints, but have difficulties in reproducibility and extrahepatic toxicity except galactosamine. Although a progress in this area has been made, search for the ideal models which accurately reflect the clinical syndrome observed in humans, must continue. (Korean J Gastroenterol 2001;37:303-311)
의학강좌 : 만성 B형간염에서의 항바이러스요법: 개정된 의료보험급여기준 중심으로
황성규 ( Seong Gyu Hwang ) 대한내과학회 2010 대한내과학회지 Vol.79 No.6
Chronic hepatitis B (CHB) can progress to cirrhosis which is one of the important clinical consequences. Recently antiviral therapy is known to reduce hepatic inflammation and prevent progression to cirrhosis and/or decompensation/hepatocellular carcinoma (HCC). When to start and stop, how to minimize antiviral resistance are major issues to be solved in antiviral therapy. To prevent HBV viral resistance, potent antiviral therapy with high genetic barriers is recommended. However we are not free from national insurance coverage in clinical practice, and there are limitations in imbursement coverage in clinical practice. Recently, guidelines of imbursement has been amended with extended coverage that goes with KASL and other guidelines. Major changes include the extension of duration of drugs beyond 3 years and approval of antiviral therapy in cirrhotic/HCC patients even with mild elevation of AST/ALT. This article reviews recent advance in management of chronic hepatitis B focusing on changes of imbursement regulation. (Korean J Med 79:635-640, 2010)
간경변증 환자에서 t - PA , Euglobulin 섬유소용해능 및 Protein C , S 의 변화와 식도정맥류출혈과의 관계
황성규(Seong Gyu Hwang),백승호(Seung Ho Baik),양동호(Dong Ho Yang),이문호(Moon Ho Lee),조용욱(Yong Wook Cho),김순길(Soon Gil Kim),오도연(Don Yeun Oh),조성원(Sung Won Cho),김선주(Sun Joo Kim),홍세용(Sae Yong Hong) 대한내과학회 1992 대한내과학회지 Vol.43 No.6
Background: Bleeding is common complication and a leading cause of death in cirrhotic patients, Accelerated fibrinolysis and coagulation inhibitor were contributing factors to bleeding. Method: In a study of 20 normal control and 20 liver cirrhosis (10 liver cirrhosis without esophageal variceal bleeding and 10 liver cirrhosis with esophageal variceal bleeding), we tried to evaluate fibrinolytic activity 8r inhibitory factors of the coagulation in liver cirrhosis and to find correlation between variceal bleeding and parameters of fibrinolysis % coagulation inhibitors. Results: 1) t-PA antigen was significantly increased(p <0.05) in patients with liver cirrhosis(22.2±12.5ng/ml) than in normal contro1(3.9±1.9ng/ml), but there was no statistically significant increase in cirrhotic patients with bleeding(26.2±13.8ng/ml) as compared to cirrhotic patients without bleeding(18.2±10.1ng/ml). 2) Euglobulin fibrinolytic activity was significantly higher(p<0,05) in patients with liver cirrhosis(145±37.6 BAU) than in normal control(91±7.8 BAU), but there was no statistically significant increase in cirrhotic patients with bleeding(150±64 BAU)as compared to cirrhotic patients without bleeding(131±22 BAU). 3) The activities of protein C was significantly lower(p<0.05) in patient with bleeding(41±9%) than in patient siwthout bleeding(54±18%). 4) The activities of protein S was lower in patient with bleeding(62±18%) than in patients without bleeding group(77±17%), but there was no statistical significance. 5) There was a significantly linear correlatian between t-PA antigen and euglobulin fibrinolytic activity in normal control and in patients with liver cirrhosis (r=0.807, p<0.01). Conclusion: Fibrinolytic activity(t-PA k euglobulin fibrinolytic activity) was increased in cirrhotic patients, but there was no statistically significant increase of fibrinolytic activity with relation to esophageal variceal bleeding. The activities of protein C was significantly decreased in liver cirrhosis with relation to esophageal variceal bleeding.